About Precede Biosciences
Precede Biosciences is a precision diagnostics and data company that unlocks genome-wide transcriptional biology through a novel, comprehensive epigenomics approach from a single blood draw. Its proprietary liquid biopsy platform integrates a novel assay with advanced machine learning to enable researchers and clinicians to better understand disease biology in real time. By partnering with developers of new medicines and advancing its own diagnostic tests, the company aims to increase drug development success rates and enable minimally invasive diagnostics for patients.
Company details
Funding
Total raised
$132M
Last stage
Series B
Investors
Founders
Rehan Verjee
Founding CEO of Precede Biosciences. Previously a member of the Healthcare Executive Committee at Merck KGaA, serving as President of EMD Serono and Chief Marketing and Strategy Officer.
LinkedInSylvan Baca
Co-founder of Precede Biosciences. Research originated at the Dana-Farber Cancer Institute.
Matthew Freedman
Professor and co-founder of Precede Biosciences, affiliated with Dana-Farber Cancer Institute. Named to the David Goldstein Chair at Dana-Farber in support of kidney cancer research.
Wouter Meuleman
PhD scientist and Partner at Illumina Ventures; joined Precede Bio's Board of Directors in January 2026 as part of the Series B financing.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.